Resumen

AZPIRI-LOPEZ, José Ramón et al. Position paper on the results of Symplicity HTN-3 trial. Grupo de estudio de la hipertensión arterial resistente. Arch. Cardiol. Méx. [online]. 2015, vol.85, n.2, pp.154-157. ISSN 1665-1731.  https://doi.org/10.1016/j.acmx.2014.11.007.

Renal artery denervation has shown to be an effective treatment for resistant hypertension. Symplicity HTN 1 and 2 trials showed in small and uncontrolled groups, significant systolic blood pressure reductions down to 30 mm Hg. Symplicity HTN-3, a double blind, randomized, placebo controlled clinical trial shaded this initial enthusiasm. Surprisingly, their results showed that renal denervation has a similar effect to placebo. Pre-specified subgroup analysis showed that non-black race individuals, younger than 65 years and with normal renal function, had a statistically significant systolic blood pressure decrease. This manuscript critically appraises the Symplicity HTN-3 trial, proposing possible explanations for the results. Also declares our group position and future actions regarding renal denervation.

Palabras llave : Catheter ablation; Renal denervation; Resistant hypertension; Systemic arterial hypertension; Symplicity trial.

        · resumen en Español     · texto en Español     · Español ( pdf )